The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Open accessAbstract
AIMS/HYPOTHESIS: Diabetes treatments were related with either an increased or reduced risk of cancer. There is ongoing debate about a potential protective action of metformin. To summarize evidence on the association between metformin and risk of cancer and cancer mortality in patients with diabetes. DATA SOURCE: MEDLINE and EMBASE (January 1966-April 2012). We selected randomized studies comparing metformin and other hypoglycaemic agents and observational studies exploring the association between exposure to metformin and cancer. Outcomes were cancer mortality, all malignancies and site-specific cancers. RESULTS: Of 25307 citations identified, 12 randomized controlled trials (21,595 patients) and 41 observational studies (1,029,389 patients) met the inclusion criteria. In observational studies there was a significant association of exposure to metformin with the risk of cancer death [6 studies, 24,410 patients, OR:0.65, 95%CI: 0.53-0.80], all malignancies [18 studies, 561,836 patients, OR:0.73, 95%CI: 0.61-0.88], liver [8 studies, 312,742 patients, OR:0.34; 95%CI: 0.19-0.60] colorectal [12 studies, 871,365 patients, OR:0.83, 95%CI: 0.74-0.92], pancreas [9 studies, 847,248 patients, OR:0.56, 95%CI: 0.36-0.86], stomach [2 studies, 100701 patients, OR:0.83, 95%CI: 0.76-0.91], and esophagus cancer [2 studies, 100694 patients, OR:0.90, 95%CI: 0.83-0.98]. No significant difference of risk was observed in randomized trials. Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma. CONCLUSIONS/INTERPRETATION: Results suggest that Metformin might be associated with a significant reduction in the risk of cancer and cancer-related mortality. Randomized trials specifically designed to evaluate the efficacy of metformin as an anticancer agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“long-term use of metformin in type 2 diabetes patients has been linked to a decline in tumor incidence and a reduced rate of cancer-related deaths.192–196”
From Drug repurposing for cancer therapy (2024) · cites this paper as [193]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Franciosi et al., 2013
In the citing paper
“this finding has subsequently been confirmed in several other studies(7–10).”
In the citing paper
“Originally introduced for the treatment of diabetes, metformin is now gaining attention as a potential anti-cancer agent (7–10) (Figure 1).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,232
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,287
Research works printed but not linked: 1
- S Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breastcancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 430
Metformin and health outcomes: An umbrella review of systematic reviews with meta‐analyses
Li, X., Celotto, S., Pizzol, D., Gašević, D., Ji, M., Barnini, T., Solmi, M., Stubbs, B., Smith, L., Sánchez, G. F. L., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13536 · Cited by 27
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis
Grossmann, M. E., Yang, D.-Q., Guo, Z., Potter, D. A., & Cleary, M. P. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0032-z · Cited by 28
Vascular AMPK as an attractive target in the treatment of vascular complications of obesity
García‐Prieto, C. F., Gil‐Ortega, M., Aránguez, I., Ortiz-Besoain, M., Somoza, B., & Fernández‐Alfonso, M. S. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.02.017 · Cited by 28
Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma
Gerthofer, V., Kreutz, M. P., Renner, K., Jachnik, B., Dettmer, K., Oefner, P. J., Riemenschneider, M. J., Proescholdt, M. A., Vollmann‐Zwerenz, A., Hau, P., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092586 · Cited by 28
The double trouble of metabolic diseases: the diabetes–cancer link
Tudzarova, S., & Osman, M. A. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-11-1550 · Cited by 26
Calip, G. S., Yu, O., Elmore, J. G., & Boudreau, D. M. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0744-3 · Cited by 26
Chen, C. B., Eskin, M., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2018) · BMC Cancer · doi:10.1186/s12885-017-3934-9 · Cited by 26
Yoshida, J., Ishikawa, T., Endo, Y., Matsumura, S., Ota, T., Mizushima, K., Hirai, Y., Oka, K., Okayama, T., Sakamoto, N., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7595 · Cited by 26
Metformin Use and the Risk of Cancer in Patients with Diabetes: A Nationwide Sample Cohort Study
Oh, T. K., & Song, I. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0427 · Cited by 26
Magdy, S., Alaaeldin, E., Fathalla, Z. M. A., Alaaeldin, R., Elrehany, M. A., Saber, E. A., Abdel-Aziz, R. T. A., & Mansour, H. F. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121781 · Cited by 25
Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes
Hagberg, K. W., McGlynn, K. A., Sahasrabuddhe, V. V., & Jick, S. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.447 · Cited by 25
Fighting obesity: When muscle meets fat
Yang, X., Bi, P., & Kuang, S. (2014) · Adipocyte · doi:10.4161/21623945.2014.964075 · Cited by 25
Assi, A. A., Posty, S., Lamarche, F., Chebel, A., Guitton, J., Cottet‐Rousselle, C., Prudent, R., Lafanéchère, L., Giraud, S., Dallemagne, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06668-9 · Cited by 27
Lamichhane, S., Bastola, T., Pariyar, R., Lee, E.-S., Lee, H.-S., Lee, D., & Seo, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030674 · Cited by 24
Fang, C.-W., Yang, J., Chiang, J., Shieh, P., Tsai, F., Tsai, C.-W., & CHANG, W.-S. (2023) · Biomedicine · doi:10.37796/2211-8039.1408 · Cited by 23
Moradinazar, M., Najafi, F., Rajati, F., Sarokhani, D., & Bavandpour, M. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_62_21 · Cited by 23
Association of diabetes and cancer mortality in American Indians: the Strong Heart Study
Best, L. G., García‐Esquinas, E., Yeh, J.-L., Yeh, F., Zhang, Y., Lee, E. T., Howard, B. V., Farley, J. H., Welty, T. K., Rhoades, D. A., et al. (2015) · Cancer Causes & Control · doi:10.1007/s10552-015-0648-7 · Cited by 24
He, X., Yao, M., Zhu, M., Liang, D.-L., Guo, W., Yang, Y., Zhao, R., Ren, T., Ao, X., Wang, W., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1057-0 · Cited by 23
Thymic emigration patterns in patients with type 2 diabetes treated with metformin
Dworacki, G., Urazayev, O., Bekmukhambetov, Y., Iskakova, S., Frycz, B. A., Jagodziński, P. P., & Dworacka, M. (2015) · Immunology · doi:10.1111/imm.12522 · Cited by 23
Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study
MacKenzie, T. A., Zaha, R. L., Smith, J., Karagas, M. R., & Morden, N. E. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0152-4 · Cited by 22
Machado, A. D. B., dos Reis, V. M. S. F., Weber, S. F., Jauckus, J., Brum, I. S., Corleta, H. V. E., Strowitzki, T., Capp, E., & Germeyer, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.5041 · Cited by 22
Szymczak-Pajor, I., Drzewoski, J., Świderska, E., Strycharz, J., Gabryanczyk, A., Kasznicki, J., Bogdańska, M., & Śliwińska, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010115 · Cited by 23
Clinical benefits of metformin in gynecologic oncology
Imai, A., Ichigo, S., Matsunami, K., TAKAGI, H., & Yasuda, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3262 · Cited by 22
In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin
Wang, D., & Wu, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3267 · Cited by 22
Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients
Goossens, M. E., Buntinx, F., Zeegers, M. P., Driessen, J. H. M., Bruin, M. L. D., & de Vries, F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12740 · Cited by 22
Use of statins offsets insulin‐related cancer risk
Kautzky‐Willer, A., Stefan Thurner, A., & Klimek, P. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12567 · Cited by 22
No association between metformin use and survival in patients with pancreatic cancer
Frouws, M. A., Mulder, B. G. S., Bastiaannet, E., Zanders, M. M. J., van Herk‐Sukel, M. P. P., de Leede, E. M., Bonsing, B. A., Mieog, J. S. D., van de Velde, C. J. �., & Liefers, G. (2017) · Medicine · doi:10.1097/md.0000000000006229 · Cited by 22
Oliveira, V. C., Constante, S. A. R., Orsolin, P. C., Nepomuceno, J. C., de Rezende, A. A. A., & Spanó, M. A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.05.052 · Cited by 22
Markowicz-Piasecka, M., Sadkowska, A., Sikora, J., Broncel, M., & Huttunen, K. M. (2020) · Pharmaceuticals · doi:10.3390/ph13100323 · Cited by 21
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Mallardo, D., Woodford, R. G., Menzies, A. M., Zimmer, L., Williamson, A. P., Ramelyte, E., Dimitriou, F., Wicky, A. M., Wallace, R., Mallardo, M., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04607-4 · Cited by 21
Antidiabetic Drugs in Breast Cancer Patients
Garczorz, W., Kosowska, A., & Francuz, T. (2024) · Cancers · doi:10.3390/cancers16020299 · Cited by 22
Nie, S., Chen, H., Zhuang, M., & Lü, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.16.6863 · Cited by 21
Chen, C. B., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.65 · Cited by 21
Pal, R. S., Jawaid, T., Rahman, M. A., Verma, R. K., Patra, P. K., Vijaypal, S. V., Pal, Y., & Upadhyay, R. (2025) · Biochimie · doi:10.1016/j.biochi.2025.03.002 · Cited by 21
Zheng, Z., Zhu, W., Yang, B., Chai, R., Liu, T., Li, F., Ren, G., Ji, S., Liu, S., & Li, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.7999 · Cited by 20
Cancer Prevention: Lessons Learned and Future Directions
Dunn, B. K., & Kramer, B. S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.003 · Cited by 21
Chang, M. S., Hartman, R. I., Xue, J., Giovannucci, E. L., Nan, H., & Yang, K. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0376 · Cited by 20
Cho, W.-R., Wang, C., Tsai, M., Chou, C., Liu, Y., Wu, Y., Lin, M., Chen, K., Chuang, C., Huang, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247231 · Cited by 20
Liu, C., Sun, J., Xu, J., Qian, X., Hong, S., Xu, M., An, Y., Xia, Q., Hu, J., & Wang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865988 · Cited by 20
Diabetes, metformin and cancer risk in myotonic dystrophy type I
Alsaggaf, R., Pfeiffer, R. M., Wang, Y., George, D. M. M. S., Zhan, M., Wagner, K. R., Amr, S., Greene, M. H., & Gadalla, S. M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32801 · Cited by 21
Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.
Wu, G., Zhang, X., Luo, Z., Yan, J., Pan, S., Ying, X., Pan, J., & Zhang, G.-F. (2015) · Europe PMC (PubMed Central) · Cited by 19
Metformin and long non-coding RNAs in breast cancer
Gholami, M., Klashami, Z. N., Ebrahimi, P., Mahboobipour, A. A., Farid, A. S., Vahidi, A., Zoughi, M., Asadi, M., & Amoli, M. M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03909-x · Cited by 21
Metformin exposure and survival in head and neck cancer: A large population-based cohort study
Alcusky, M. J., Keith, S. W., Karagiannis, T., Rabinowitz, C., Louis, D. Z., & Maio, V. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12820 · Cited by 19
Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a
de Queiroz, E. A. I. F., Akamine, E. H., de Carvalho, M. H. C., Sampaio, S. C., & Fortes, Z. B. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.028 · Cited by 19
Qaoud, M. T., Almasri, I. M., & Önkol, T. (2021) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2021.70105 · Cited by 18
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression
Papachristodoulou, A., Heidegger, I., Virk, R. K., Di Bernardo, M., Kim, J. Y., Laplaca, C., Picech, F., Schäfer, G., De Castro, G. J., Hibshoosh, H., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.07.016 · Cited by 18
Francesco, S. D., Robuffo, I., Caruso, M., Giambuzzi, G., Ferri, D., Militello, A., & Toniato, E. (2019) · Medicina · doi:10.3390/medicina55030062 · Cited by 19
Peng, C., Jiang, N., Zhao, J.-F., Liu, K., Jiang, W., & Cao, P. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115408 · Cited by 18
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients
Gardini, A. C., Filippi, R., Rimini, M., Rapposelli, I. G., Fornaro, L., Silvestris, N., Aldrighetti, L. A., Aimar, G., Rovesti, G., Bartolini, G., et al. (2021) · Oncology · doi:10.1159/000512796 · Cited by 18
Screening of GPCR drugs for repurposing in breast cancer
Abdulkareem, N. M., Bhat, R. R., Powell, R. T., Chikermane, S. G., Yande, S., Trinh, L., Abdelnasser, H. Y., Tabassum, M., Ruiz, A., Sobieski, M. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1049640 · Cited by 18
Anti-tumour effect of metformin in canine mammary gland tumour cells
Saeki, K., Watanabe, M., Tsuboi, M., Sugano, S., Yoshitake, R., Tanaka, Y., Ong, S. M., Saito, T., Matsumoto, K., Fujita, N., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.026 · Cited by 18
Kim, N. H., Suh, J. Y., Park, J. H., Park, D. I., Cho, Y. K., Sohn, C. I., Choi, K.-Y., & Jung, Y. S. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.2.347 · Cited by 18
Metabolic Alterations at the Crossroad of Aging and Oncogenesis
Raffaghello, L., & Longo, V. D. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.01.003 · Cited by 19
Lee, D. J., McMullen, C. P., Foreman, A., Huang, S. H., Lu, L., Xu, W., de Almeida, J. R., Liu, G., Bratman, S. V., & Goldstein, D. P. (2019) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-019-0348-5 · Cited by 18
Sun, L., Yao, H.-J., Li, J.-C., Zhao, B., Wang, Y., & Zhang, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s382519 · Cited by 17
Mesquita, L. A., Spiazzi, B. F., Piccoli, G. F., Nogara, D. A., da Natividade, G. R., Garbin, H. I., Wayerbacher, L. F., Wiercinski, V. M., Baggio, V. A., Zingano, C. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15509 · Cited by 19
Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?
Valli, D., Gruszka, A., & Alcalay, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061892 · Cited by 19
Xie, H. W., Li, M., & Zheng, Y. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.01.007 · Cited by 16
Zhou, G., Yu, J., Wang, A., Liu, S.-H., Sinnett‐Smith, J. W., Wu, J. X., Sanchez, R., Nemunaitis, J. J., Ricordi, C., Rozengurt, E., et al. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666151222145551 · Cited by 16
Pasanisi, P., Gargano, G., Mauro, M. G. D., Cortellini, M., Casagrande, A., Villarini, A., Bruno, E., Roveda, E., Saibene, G., Venturelli, E., et al. (2017) · Tumori Journal · doi:10.5301/tj.5000599 · Cited by 18
Is metformin a geroprotector? A peek into the current clinical and experimental data
Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16
Wang, M., Gong, W., Lu, F., Hu, R., He, Q., & Yu, M. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00684-y · Cited by 16
Chen, H.-F., Chang, Y., Ko, M.-C., & Li, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.001 · Cited by 16
Landim, B. C., de Jesus, M. M., Bosque, B. P., Zanon, R. G., da Silva, C. V., Góes, R. M., & Ribeiro, D. L. (2018) · The Prostate · doi:10.1002/pros.23517 · Cited by 16
Ji, J., Sundquist, J., & Sundquist, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04814-4 · Cited by 16
Harewood, R., Disney, R., Kinross, J. K., von Wagner, C., & Cross, A. J. (2021) · Cancer Causes & Control · doi:10.1007/s10552-021-01472-8 · Cited by 16
Wang, N. F., Jue, T. R., Holst, J., & Gunter, J. H. (2022) · BJUI Compass · doi:10.1002/bco2.187 · Cited by 15
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
Saito, Y., Noto, H., Takahashi, O., & Kobayashi, D. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000387 · Cited by 15
The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients
Tsou, Y.-A., Chang, W., Lu, J.-J., Wu, T.-F., Chen, H.-L., Chen, C., & Tsai, M.-H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6083-5 · Cited by 15
Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects
Das, B. K., & Gadad, P. C. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100025 · Cited by 15
Ghiasi, B., Sarokhani, D., Najafi, F., Motedayen, M., & Dehkordi, A. H. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190215123759 · Cited by 15
Breast cancer fibroblasts and cross-talk
Magesh, P., Thankachan, S., Venkatesh, T., & Suresh, P. S. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.07.011 · Cited by 14
Prevention of hepatocellular carcinoma and surveillance of high risk patients
Kaya, E., Mazzolini, G. D., Yilmaz, Y. N., & Canbay, A. E. (2021) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2021.2021.0033 · Cited by 14
Metformin and the risk of renal cell carcinoma: a case–control analysis
Becker, C., Jick, S. S., Meier, C. R., & Bodmer, M. (2016) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000246 · Cited by 14
Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes
Tseng, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587666 · Cited by 14
Use of Non-Insulin Therapies for Type 1 Diabetes
Garg, S. K., Michels, A. W., & Shah, V. N. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0281 · Cited by 14
Manna, E. D. F., Serrano, D., Aurilio, G., Bonanni, B., & Lazzeroni, M. (2023) · Healthcare · doi:10.3390/healthcare11162360 · Cited by 14
Chen, M., Shen, C., Chen, Y., Chen, Z., Zhou, K., Chen, Y., Li, W., Zeng, C., Qing, Y., Wu, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101645 · Cited by 15
Chemopreventive Effect of Metformin on Gastric Cancer Development
Cheung, K. S., Chung, F. K. L., & Leung, W. K. (2021) · Gut and Liver · doi:10.5009/gnl210132 · Cited by 13
Zahra, M. H., Afify, S. M., Hassan, G., Nawara, H. M., Kumon, K., Seno, A., & Seno, M. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3661 · Cited by 13
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity
Zhang, Q., Schmandt, R. E., Celestino, J., McCampbell, A. S., Yates, M. S., Urbauer, D. L., Broaddus, R. R., Loose, D. S., Shipley, G. L., & Lu, K. H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.006 · Cited by 13
Metformin displays in vitro and in vivo antitumor effect against osteosarcoma
Ko, Y., Choi, A., Lee, M., & Lee, J. A. (2016) · Korean Journal of Pediatrics · doi:10.3345/kjp.2016.59.9.374 · Cited by 13
Shah, R. R. (2016) · Drug Safety · doi:10.1007/s40264-016-0485-y · Cited by 13
Karadeniz, Z., Aynacıoğlu, A. Ş., Bılır, A., & Tuna, M. Y. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109420 · Cited by 13
Epidemiology and Risk Factors of Hepatocellular Carcinoma
El‐Serag, H. B., Balakrishnan, M., & Natarajan, Y. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch14 · Cited by 13
Markowicz-Piasecka, M., Sadowski, K., Huttunen, J., Sikora, J., & Huttunen, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115642 · Cited by 12
Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study
Kristensen, D. T., Øvlisen, A. K., Jakobsen, L. H., Severinsen, M. T., Hannig, L. H., Starklint, J., Hilsøe, M. H., Vallentin, A. P., Brabrand, M., Hasselbalch, H. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012266 · Cited by 12
Faillie, J., & Suissa, S. (2014) · Therapies · doi:10.2515/therapie/2014207 · Cited by 19
Al‐Omari, A., Abdelkhaleq, H., Al-Hussaini, M. A., Turfa, R., Awad, N., Hassan, M. M., Alfaqih, M. A., & Garrett, C. R. (2018) · Journal of Global Oncology · doi:10.1200/jgo.18.00018 · Cited by 12
Obesity, Type-2 Diabetes and Cancer: Mechanistic Insights
Kashfi, K., Rosen, C. L., & Aslan, M. (2019) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2019032959 · Cited by 12
Metformin is a Novel Suppressor for Vimentin in Human Gastric Cancer Cell Line.
Valaee, S., Shamsara, M., & Yaghoobi, M. M. (2021) · PubMed Central · doi:10.22088/ijmcm.bums.10.3.200 · Cited by 12
Dąbrowski, M., & Grondecka, A. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.58666 · Cited by 12
Вацеба, Т. С. (2020) · Wiadomości Lekarskie · doi:10.36740/wlek202005124 · Cited by 11
Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma
Novik, A. V. N., Protsenko, S. A., Балдуева, И. А., Berstein, L. M., Anisimov, V. N., Zhuk, I. N., Semenova, A. I. S., Latipova, D. K., Ткаченко, Е. В., & Semiglazova, Т. Y. (2021) · The Oncologist · doi:10.1002/onco.13761 · Cited by 11
Effect of metformin on apoptosis induction in ovarian cancer cells
Rogalska, A., Forma, E., Ciesielski, P., Bryś, M., Krześlak, A., & Marczak, A. (2014) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2014.43817 · Cited by 11
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 11
Spoerl, S., Gerken, M., Schimnitz, S., Taxis, J., Fischer, R., Lindner, S. R., Ettl, T., Ludwig, N., Spoerl, S., Reichert, T. E., et al. (2022) · Current Oncology · doi:10.3390/curroncol29120758 · Cited by 11
Yang, B., Huang, C., Yu, T., Zhou, S., Liu, Q., Liu, G.-J., Chen, S., & Han, F. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000483 · Cited by 11
Panahandeh, P., Bertelsen, B.-E., Viste, K., Chatziioannou, A. C., Bellerba, F., Robinot, N. R., Trolat, A., Flågeng, M. H., Scalbert, A., Keski‐Rahkonen, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01705-9 · Cited by 10
Metadata
- Authors
- Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A.
- Affiliations
- University of Naples Federico II (IT)
- The University of Sydney (AU)
- Corresponding author
- Franciosi, Monica
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-02
- Volume
- 8
- Issue
- 8
- Pages
- e71583
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3732236
- OpenAlex
- W2081540191
- Cited by
- 428
- References
- 89
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 19 · 2023: 27 · 2022: 18 · 2021: 29 · 2020: 31 · 2019: 36 · 2018: 31 · 2017: 44 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 5
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- type 2 diabetes, cancer risk, cancer mortality, liver cancer, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, site-specific cancer, chemoprevention, antidiabetic drugs, drug safety, randomized controlled trials, observational studies, breast cancer, lung cancer, ovarian cancer, prostate cancer, bladder cancer, kidney cancer, melanoma
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
